Document:

Amended and Restated Separation Agreement

 Exhibit 10.1 
 AMENDED AND RESTATED 
 SEPARATION AGREEMENT AND GENERAL RELEASE 
 This Amended and Restated Separation Agreement and General Release (“Agreement”) is made between Alexander M. Winiecki, whose address is
12 Boylston Terrace, Amherst NH 03031 (“Employee”) and Brookstone, Inc., a Delaware corporation (“Employer” or “Company”). 
 WHEREAS, Employer and Employee are parties to an Employment Agreement dated as of October 4, 2005 (“Employment Agreement”); 
 WHEREAS, Employee held the position of Executive Vice President, Store Operations of the Employer; 
 WHEREAS, effective July 12, 2006 (“Termination Date”), Employee resigned his position held with Employer and any affiliated entities; and 
 WHEREAS, the Company and the Employee have entered into that certain Separation Agreement and General Release, dated as of August 10, 2006 (the “Original Separation Agreement”), in connection with the
termination of the Employee’s employment; 
 WHEREAS, pursuant to the Original Separation Agreement, Employee was deemed to have
resigned his employment with Employer without Good Reason pursuant to Section 7(d) of the Employment Agreement as of the Termination Date, and all of his positions as an officer of Employer and any of its affiliated entities terminated as of
that date; and 
 WHEREAS, the Company and the Employee desire to amend and restate the Original Separation Agreement in its entirety as set
forth herein. 
 NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Company and the Employee agree that the Original Separation Agreement is hereby amended and restated in its entirety as follows: 
 1. The Parties agree that, except as expressly and specifically provided herein, the Employment Agreement is terminated insofar as it may require the Company to make any further payments or to provide any further
benefits to Employee. 
 For avoidance of doubt, Sections 8 and 11 of the Employment Agreement shall remain in full force and effect and are
incorporated into this Agreement by reference. A copy of Sections 8 and 11 (“Restrictive Covenants”) are attached hereto as Exhibit A. Section references in Exhibit A are to the Employment Agreement. 
 2. Employee acknowledges that, effective July 12, 2006, his employment and any and all positions he held with Employer and any affiliated entities
were terminated by him without Good Reason, and as of that date he relinquished any and all of his authorities with each of those entities. Employee agrees and acknowledges that he has received a final payroll check in the 

  

 1 

 
gross amount of $29,166, which amount represents payment in full to Employee for Employee’s base salary through July 31, 2006, payment for 160
hours of vacation for fiscal year 2006 in accordance with New Hampshire law, less applicable payroll taxes and deductions. Employee agrees and acknowledges that Employee has been reimbursed for all business related travel and entertainment expenses
incurred through the Termination Date. Employee agrees that Employee has no right to any further compensation, including medical benefits, except in accordance with the terms of this Agreement. 
 3. In consideration of Employee’s commitments as set forth in this Agreement, including the release of claims set forth below, Employer will
continue to pay Employee, as severance pay and in accordance with the provisions of Section 3, Employee’s regular base salary, less legally required deductions and deductions requested by Employee, for ten (10) months following the
Termination Date (the “Severance Period”). 
  

	 	a.	Severance payments will be made monthly according to the same schedule that Employee received Employee’s base salary prior to the Termination Date, except that severance
payments will not commence until the first regularly scheduled pay date following the Effective Date of this Agreement as defined in Section 13. Such first severance payment shall include all severance pay due Employee pursuant to this
Agreement from the Termination Date through the closing date of the pay period in which the first severance payment is made, less deductions required by law or requested by Employee. All other severance payments shall consist of Employee’s
regular monthly base salary, less deductions required by law or requested by Employee. For the avoidance of doubt, Employee acknowledges and agrees that the aggregate severance payments shall equal $291,660 (subject to any deductions required by law
or requested by Employee). 

  

	 	b.	 Subject to Section 3(c) below, from the Termination Date until October 4, 2008 (the “Benefit Continuation Period”), Employee will continue to
participate in those Brookstone group health and dental plans, under the terms of any such plans as may be in effect during such period, on the same cost-sharing basis as during Employee’s tenure with Brookstone as a full-time employee. During
the Severance Period, Employee’s premium contribution will be deducted automatically from the severance payments, and Employee’s signature on this Agreement serves as authorization for such deductions. During the portion of the Benefit
Continuation Period following the Severance Period, Employee shall pay his premium contribution to Employer in cash at or prior to the end of each pay period or in such other manner as may be mutually agreed upon by him and Employer. To the extent
that Employee has elected to include qualified dependents under the benefits made available under Brookstone’s group health and dental insurance plans, the dependants will also continue to so participate. In no event shall the Employee
participate in any Employer bonus or profit sharing plan the Termination Date. Employee acknowledges and agrees (for the avoidance of doubt) that, for purposes of the Brookstone Company, Inc. Retiree Health Plan, his termination 

  

 2 

	 	 
of employment shall not be deemed to have occurred as a result of his retirement from service with the Company. 

  

	 	c.	Notwithstanding the foregoing, if during the period in which salary and/or benefits continue pursuant to the provisions of Section 3, Employee accepts other employment
providing him medical and dental coverage, the continuation of his medical and dental coverage hereunder shall immediately cease. 

 4. You agree that the payments and other benefits provided under this Agreement are in complete satisfaction of any and all compensation due to you for services provided to Brookstone, and that they represent a benefit to which you are not
otherwise entitled. You understand and acknowledge that you will not continue to earn vacation or other paid time off after the Termination Date and your participation in all employee benefit and fringe benefit plans of Brookstone will end as of the
Termination Date excepting continuation rights as may be contained in this Agreement. 
 5. Upon the termination or expiration of the Benefit
Continuation Period in accordance with Section 3(b) above, you and/or your qualified beneficiaries will become eligible to elect to continue to participate in Brookstone’s group health plans pursuant to the Consolidated Omnibus Budget
Reconciliation Act of 1985, Title X, as amended (“COBRA”) at your sole cost for limited periods of time as prescribed by COBRA. You will receive information regarding your COBRA rights at the end of the Benefit Continuation Period.

 6. Employee’s Equity Securities. 
  

	 	a.	 OSIM Brookstone Holdings, L.P. (“OBH”) is hereby exercising its rights under the Second Amended and Restated Limited Partnership Agreement of OBH LP (the
“Partnership Agreement”), dated as of October 4, 2005, among OSIM Brookstone Holdings, Inc. (“OBH GP”) and each of the limited partners of OBH LP, to purchase the 61,409 Class A Common Limited Partnership Interests of
OBH LP (the “Class A Interests”) and the 2,288 Class B Common Limited Partnership Interests of OBH LP (the “Make-Up Class B Interests”, and collectively with the Class A Interests, the “OBH LP
Interests”) held by him. Subject to the terms and conditions set forth in this Agreement, Employee hereby agrees to sell to OBH LP, and OBH LP hereby agrees to purchase and accept from Employee on the date hereof, Employee’s right, title
and interest in and to the OBH LP Interests in exchange for 455.56 shares of common stock, par value $0.01 per share, of Brookstone Holdings Corp. (the “Pass-Through Common Stock”), and Employee hereby agrees to sell to Brookstone Holdings
Corp., and Brookstone Holdings Corp. hereby agrees to purchase and accept from Employee, the Pass-Through Common Stock on the first day after the date hereof, for a total purchase price equal to Six Hundred Fourteen Thousand Ninety Dollars
($614,090.00), which Employee agrees shall, notwithstanding anything to the contrary contained in the Partnership Agreement, be payable (without interest) in two equal installments by wire transfer of immediately available funds in accordance with
wire transfer instructions set forth on the signature pages hereto, as follows: the first installment shall be paid on January 2, 2007 and the second installment shall be paid on July 2, 2007. For the avoidance of doubt, Employee and OBH
LP hereby acknowledge and agree that the 

  

 3 

	 	 
Call Price and the Cost Price (each, as defined in the Partnership Agreement) of the Make-Up Class B Interests is zero. 

  

	 	b.	In accordance with Section 9.1(c) of the Partnership Agreement and Section 2.1 of the Shareholders Agreement, dated as of October 4, 2005, among OBH GP and each of
the shareholders of OBH GP, Employee agrees to transfer to OBH GP the 61,409 ordinary shares in the capital of OBH GP held by him (the “OBH GP Shares”) for no additional consideration, simultaneously with the repurchase by OBH LP of the
OBH LP Interests on the date hereof; 

  

	 	c.	Employee agrees to execute and deliver to the applicable party a written assignment, the form of which is attached hereto as Exhibit B, with respect to each of the (i) OBH LP
Interests, (ii) OBH GP Shares and (iii) Pass-Through Common Stock. 

  

	 	d.	The OBH LP Interests and the OBH GP Shares held by Employee are owned of record and beneficially by Employee and represent all of the equity interests held by Employee and his
direct and indirect Permitted Transferees (as defined in the Partnership Agreement) in the Applicable Entities (as defined in the Partnership Agreement), and Employee has good and marketable title to the OBH LP Interests and the OBH GP Shares, free
and clear of any Liens (as defined in the Partnership Agreement) and the execution by Employee of this Agreement shall not result in the imposition of any Lien upon the OBH LP Interests, the OBH GP Shares or the Pass-Through Common Stock. Employee
agrees that, upon his receipt of the Pass-Through Common Stock, he will not transfer any of the Pass-Through Common Stock other than to Brookstone Holdings Corp. in accordance with Section (a) above. 

  

	 	e.	Employee and OBH LP agree that the execution of this Agreement shall be deemed to satisfy all requirements with respect to the delivery of a Call Notice under the Partnership
Agreement and, notwithstanding the provisions contained in Section 9.6 of the Partnership Agreement, the closing of the purchase of Employee’s OBH LP Interests, OBH GP Shares and Pass-Through Common Stock shall take place on the date
hereof and the first day hereafter, as provided herein. 

  

	 	f.	Employee acknowledges and agrees that in accordance with the terms of the Restricted Interest Award Agreement (Time Vested) and the Restricted Interest Award Agreement (IRR Vested),
each dated as of October 4, 2005, between OBH LP and Employee, all Restricted IRR Interests and Restricted Time Interests, including those Restricted Time Interests that are Vested Class B Interests (each as defined in such award agreements)
were automatically forfeited by him upon the Termination Date. 

  

 4 

	 	g.	OBH LP and the Company represent and warrant that (A) this Agreement and each instrument executed and to be executed by the Company or any of its affiliated entities
(“Company Entities”) in connection herewith constitute the legal, valid and binding obligations of the applicable Company Entity, enforceable against it in accordance with their respective terms, except as limited by bankruptcy, insolvency
or other Laws affecting generally the enforcement of creditors’ rights and doctrines of equity relating to the availability of specific performance as a remedy, and (B) the execution and delivery of this Agreement and each instrument
executed and to be executed by a Company Entity in connection herewith, the consummation of the transactions contemplated herein, and the performance of, fulfillment of and compliance with the terms and conditions hereof and thereof by the Company
Entities does not and will not: (i) conflict with or result in a breach of the organizational documents of any Company Entity, including any amendments and modifications thereto; or (ii) violate or conflict with or constitute a default
under any agreement, instrument or writing of any nature to which any Company Entity is a party or by which any Company Entity or its assets or properties may be bound, which violation, conflict or default would have a material adverse effect on any
Company Entity’s ability to consummate the transactions contemplated hereby. 

  

	 	h.	Employee and OBH LP agree to treat the above repurchase of the OBH LP Interests by OBH LP as a distribution to Employee under Section 731 of the Internal Revenue Code of 1986,
as amended (the “Code”) and that all income tax returns, reports and IRS forms filed by them shall be prepared consistently with such treatment. Employee and Brookstone Holdings Corp. agree to treat the above sale of the Pass-Through
Common Stock by Employee to Brookstone Holdings Corp. as a complete redemption of Employee’s interest in Brookstone Holdings Corp. under Section 302(b)(3) of the Code for all income tax purposes and that all income tax returns, reports and
IRS forms filed by them shall be prepared consistently with such treatment. 

 7. In consideration of this Agreement, including
without limitation the making of the severance payments to you provided for in Section 3, Employee, on behalf of himself, his agents, heirs, representatives, assigns, executors and administrators (collectively, the “Releasors”),
hereby releases and forever discharges Employer, its affiliated entities, Brookstone Holdings Corp., Brookstone Acquisition Corp, OBH LP, J.W. Childs Associates, L.P., and any and all of their respective parents, subsidiaries, predecessors,
successors, assigns, employees, shareholders, members, officers, directors, agents, attorneys, representatives, affiliates, and related companies (collectively, the “Brookstone Releasees”) of and from any and all claims, causes of action,
suits, charges, debts, demands and liabilities, both in law and in equity, including without limiting the generality of the foregoing, claims, demands or actions for wages, benefits, damages, attorney’s fees, or any other form of relief
available, and any rights or claims under Title VII of the Civil Rights Act of 1964, as amended; the Age Discrimination in Employment Act of 1967, 29 U.S.C. § 621 et seq., as amended by the Older Workers Benefit Protection
Act (except for such rights 

  

 5 

 
and claims arising after the date of execution of this Agreement); the Vocational Rehabilitation Act of 1973, 29 U.S.C. § 701, as amended; the
Employee Retirement Income Security Act of 1974, 29 U.S.C. § 1001 et seq., as amended; the Americans With Disabilities Act; the Family and Medical Leave Act; the Fair Labor Standards Act; and the state human rights laws of the
state of New Hampshire, including but not limited to New Hampshire RSA 354-A; as well as any other federal, state, or local law, regulation, ordinance, judicial decision or public policy; as well as any contract, tort or other claims, whether known
or unknown, which the Releasors now have, own or hold, or claim to have, own or hold, or which the Releasors at any time heretofore had, owned or held, or claimed to have had, owned or held against any Brookstone Releasees from the beginning of the
world to the Effective Date of this Agreement, except for claims for breach of the terms of this Agreement. This shall be a full and final release of all claims, known and unknown, foreseen and unforeseen, regardless of the adequacy of the
compensation or the extent or character of Employee’s injuries and/or damages. Employee expressly acknowledge and assume all risk, chance, or hazard that any injuries and/or damages may become permanent, progressing, greater, or more extensive
than is known, anticipated, or expected. 
 Further, to the fullest extent permitted by law, Employee, on behalf of himself and all Releasors, agrees not to
lodge any formal or informal complaint in court, with any federal, state or local agency or any other forum, including without limitation arbitration, in any jurisdiction, arising out of or related to any claim described above. Employee hereby
represents and warrants that he has brought no complaint, claim, charge, action or proceeding against any of the Brookstone Releasees in any jurisdiction or forum. Employee further represents, warrants and agrees that he has not in the past and will
not in the future assign any claim to any person, corporation or other entity. 
 Execution of this Agreement by Employee operates as a complete bar and
defense against any and all of Employee’s claims against Employer and/or the other Releasees. If Employee should hereafter make any claim in any charge, complaint, action or proceeding against Employer or any other of the Releasees, this
Agreement may be raised as and shall constitute a complete bar to any such action, claim or proceeding and Employer and/or the other Releasees shall be entitled to and shall recover from Employee all costs incurred, including attorney’s fees,
in defending against any such charge, complaint, action, claim or proceeding. 
 8. You agree to indemnify and hold Employer harmless from
and against any and all loss, costs, damages, or expenses, including reasonable attorney’s fees, arising out of your breach of any of the terms in this Agreement, including, without limitation, any amounts incurred by Employer in connection
with any attempt to enforce the terms of this Agreement against Employee. 
 9. You confirm that you have returned to Brookstone any and all
Brookstone property currently in your possession or control including, without limitation, any Company vehicle, keys, access cards, computer equipment, telephones, credit cards, Brookstone documents, policies, manuals, personnel files and any other
confidential materials and agree that you shall return any such property as described in this section which you locate after the execution of this Agreement. 
 10. You agree to cooperate with Brookstone at the request of Brookstone or its counsel, upon reasonable notice, with respect to all matters arising out of or during your employment at 

  

 6 

 
Brookstone including but not limited to cooperation in connection with any judicial, administrative, or governmental investigation or proceeding. Brookstone
will reimburse to you those reasonable out-of-pocket expenses incurred by you in performance of your obligations under this Section 10. 
 11. You covenant and agree not to disclose to anyone other than your immediate family and your personal financial, tax and legal advisors any information relating to the fact or contents of this Agreement, except that you may disclose this
Agreement to the Internal Revenue Service and/or the New Hampshire Department of Employment Security if required by the applicable agency. You and Brookstone further agree that you may disclose only Section 9 of this Agreement and
Sections 8 and 11 of the Employment Agreement to current or prospective employers or other business affiliates to aid in the enforcement of those sections. You likewise authorize Brookstone to disclose and provide copies of these provisions to
any of your current or prospective employers or other business affiliates. 
 12. By signing this Agreement, you acknowledge that you:

  

	 	a.	have read this Agreement; 

  

	 	b.	understand it is a legally binding agreement and that you were advised to review it with legal counsel of your choice; 

  

	 	c.	have had, or have had the opportunity to take, twenty-one (21) calendar days to discuss it with legal counsel of your choice before signing and that, if you sign before the end
of such period, you do so of your free will and with full knowledge that you could have taken the full period; 

  

	 	d.	realize and understand that it applies to and covers all claims, demands, and causes of action of any kind whatsoever, including those under the ADEA, against Brookstone and the
Brookstone Releasees, whether or not you know or suspect them to exist at the present time; and 

  

	 	e.	understand (1) the terms of this Agreement, (2) that it is not part of an exit incentive or other employment termination program being offered to a group or class of
employees, and (3) that your signing this Agreement is done voluntarily and with the full understanding of its consequences and you have not been forced or coerced in any way to do so. 

 13. You shall have a period of seven (7) calendar days after the date you sign this Agreement to revoke and cancel it. Any revocation and
cancellation must be in writing, signed by you and received by Brookstone’s Vice President of Human Resources before the close of business of the seventh (7th) calendar day following the date you sign this Agreement. Consequently, the
Agreement shall have no force and effect until the expiration of seven (7) calendar days following the day you sign it. As of the first business day following the expiration of the seven-day revocation period the “Effective Date” of
this Agreement shall be the Effective Date under the Original Separation Agreement. 
  

 7 

 14. Each of the parties agree to the following miscellaneous provisions: 
  

	 	a.	All written notices to be given hereunder, whether pursuant to this Agreement or a provision of law, shall be given in person, by nationally recognized overnight courier service, or
by first class United States mail, postage prepaid, return receipt requested, as follows and deemed received upon the earlier of (i) when acknowledged to be received or (ii) five (5) business days after mailing:

 To Brookstone:    Brookstone, Inc.  
                                 Attn: Carol Lambert 
                                 Vice President Human Resources 
                                 One Innovation Way 
                                 Merrimack, New Hampshire 03054 
 With a copy to:        Kaye Scholer LLP 
                                 425 Park Avenue 
                                 New York, New York 10022 
                                 Fax: (212) 836-8689 
                                 Attn.: Stephen C. Koval, Esq. 
                                        
   John D. Geelan, Esq. 
 To Employee:        Alexander M. Winiecki 

                                 12 Boylston Terrace 
                                 Amherst, NH 03031 
  

	 	b.	This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable
principles of conflicts of law thereof. Any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement may be brought against either of the parties in the courts of the State of New Hampshire, or
if it has or can acquire jurisdiction, in the United States District Court for the State of New Hampshire, and each of the parties hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts) in any such action or
proceeding and waives any objection to venue laid therein. Process in any action or proceeding referred to in the preceding sentence may be served on any party anywhere in the world, whether within or without the State of New Hampshire.

  

	 	c.	 This Agreement constitutes our entire understanding and supersedes all prior agreements between us, including, for the avoidance of doubt, the Original Separation
Agreement. The Company and Employee each agree that as of the Effective Date, except as otherwise expressly and specifically provided for herein, any other agreement entered into between any of the Company Entities and the Employee shall be deemed
null and 

  

 8 

	 	 
void and of no further effect and superceded in all respects by this Agreement. 

  

	 	d.	No waiver of any rights caused by breach of any provision of this Agreement shall constitute a waiver of any prior, concurrent, or subsequent breach of the same or any other
provisions hereof, and no waiver shall be effective unless made in writing. 

  

	 	e.	This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one instrument.

  

	 	f.	Should any provision of this Agreement be held invalid, illegal or unenforceable, it shall be deemed to be modified so that its purpose can lawfully be effectuated and the balance
of this Agreement shall be enforceable and remain in full force and effect. 

  

	 	g.	Any employment tax payable as a result of this Agreement shall be the sole and exclusive responsibility of Employee. Employee acknowledges that the Company has given him no tax
advice as to the appropriate tax treatment of the transactions described in this Agreement and that any taxes owing by Employee are his sole responsibility. Employee hereby agrees to hold harmless and indemnify the Company should it be determined by
the IRS that any employment taxes (and any interest and penalties related thereto) are due with respect to the transactions described in this Agreement. 

  

	 	h.	This Agreement shall inure to the benefit of the parties hereto and their respective successors, heirs, legatees and legal representatives. 

 15. The parties hereto hereby acknowledge and agree that nothing in this Agreement shall affect the rights Employee has accrued under the Brookstone,
Inc. Pension Plan. 
  

			
	 ALEXANDER M. WINIECKI
  
 ____________________________________________________
  
 Date:________________________________________________
	 	 BROOKSTONE, INC.
  
 By:   ______________________________________________
  
 Name:_____________________________________________
  
 Title:  
_____________________________________________
  
 Date:______________________________________________

  

 9 

  

	
	 Solely with respect to Paragraph 6
  
 OSIM BROOKSTONE HOLDINGS, L.P.

	
	 By: OSIM Brookstone Holdings, Inc.,
 its general partner

	
	 By:  ______________________________________
         Name:
         Title:

	
	
	 Solely with respect to Paragraph 6.
  
 BROOKSTONE HOLDINGS CORP.

	
	
	 By:  ______________________________________
         Name:
         Title:

	

  

 10 

 EXHIBIT A 
  

 11 

 EXHIBIT B 
 FORM OF ASSIGNMENT 
 For valuable consideration, the receipt of which is hereby acknowledged,
Alexander M. Winiecki hereby [sells], assigns and transfers to __________________ all of his right, title, benefit, privileges and interest in and to the _____________________ (______) shares of [common stock] [Class A/B Interests] of ____________
(the “Company”) standing in his name on the books of the Company as of the date hereof. 
 Dated _____________,
2006 
 _______________________________________ 
 Alexander M. Winiecki 
  

 12Plasma Purchase Agreement between Bayer HealthCare LLC

 Exhibit 10.1 
 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 PLASMA PURCHASE AGREEMENT 
 THIS PLASMA PURCHASE AGREEMENT (“Agreement”) is made and entered into as of
this 03 day of December, 2003, by and between Bayer HealthCare LLC, a Delaware limited liability company, with its principal place of business in Tarrytown, New York and an address at 79 T.W. Alexander Dr., 4101 Research Commons, Research Triangle
Park, North Carolina 27610 (“Bayer”), and Nabi Biopharmaceuticals (formerly Nabi) a Delaware, corporation, with its principal place of business at 5800 Park of Commerce Blvd NW, Boca Raton, FL, 33487 (“Nabi”). 
 RECITALS 
 Nabi desires to sell, and Bayer desires to
purchase, Normal Source Plasma (“Plasma”) solely on the terms and conditions set forth in this Agreement. 
 PROVISIONS

 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and with the intent
to be legally bound hereby, Bayer and Nabi agree as follows: 
 A. Purchase and Sale of Plasma 
 1. Term of Agreement 
 Unless terminated earlier as provided in
Section C, the term of the Agreement shall commence on the Effective Date hereof and terminate on December 31, 2008 (the “Initial Term”). After the Initial Term, this Agreement may be renewed for additional five (5) year periods
upon the mutual consent of the parties. Each party agrees that it will endeavor, in good faith, to conclude any negotiations relating to such renewals no less than one (1) year before the expiration of this Agreement. 
 2. Quantity of Source Plasma 
 From and after
the Effective Date of this Agreement, Bayer agrees to purchase, and Nabi agrees to sell Plasma, produced from Approved Bayer Centers (as defined in Section A.3 below), in the quantities set forth below for the calendar years referenced below:

  

					
	 Contract Year
	 	  	 	Quantity
	 2004-
	 		 	[*****] liters
	 2005-
	 		 	[*****] liters
	 2006-
	 		 	[*****] liters
	 2007-
	 		 	[*****] liters
	 2008-
	 		 	[*****] liters

  

 1 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 
 The above Plasma volumes/quantities from 2004 through 2008 are firm commitments by both parties. 
 Nabi will sell and deliver to Bayer Plasma in monthly volume increments in accordance with an agreed upon production and delivery forecast. If
Nabi fails to provide the agreed upon volumes to Bayer during any contract year, other than a contract year that begins after the effective date of a notice of termination, then Nabi, at Bayer’s sole option, will use commercially reasonable
efforts to provide Bayer with acceptable Plasma from other sources approved by Bayer. Notwithstanding the above, Nabi shall have no obligation to provide Plasma to Bayer in the event the failure to provide the agreed upon volumes is due to a Force
Majeure event pursuant to Section D. 
 3. Approved Centers  
 Nabi will supply Plasma from Approved Bayer Centers. For purposes of this Agreement, a Center is defined as an “Approved Bayer Center”, if:
(i) the operator and the Center have received all necessary regulatory approvals and permits, including Food and Drug Administration (FDA), Quality Plasma Program (iQPP) including acceptable viral marker rates, required state licensing, and
Clinical Laboratory Inspection Act licensure and approval, and (ii) the Center has been added to, and remains on, Bayer’s List of Approved Bayer Centers (currently labeled SQID), which List of Approved Bayer Centers, as amended from time
to time by Bayer, is incorporated by reference as a material part of this Agreement. All Approved Bayer Centers must be approved by German authorities. 
 4.
Quality of Source Plasma 
 All Plasma sold to Bayer under this Agreement must be collected and processed at an Approved Bayer
Center and in accordance with the specifications currently in effect as written by Bayer (the “Bayer Specifications”). Nabi acknowledges that it has received a full, complete and accurate copy of the Bayer Specifications as in effect as of
the date of execution of this Agreement. Any revisions to the Bayer Specifications will be sent to Nabi for review. No such modification of the Bayer Specifications shall be effective until such time as Nabi consents to it in writing, which consent
shall be timely determined and not unreasonably withheld. Nabi also agrees to have all of its Approved Bayer Plasma Centers iQPP Certified and to maintain such certification for the entire term (including extension and renewal periods) of this
Agreement. Any Bayer Approved Center that is not iQPP Certified during any portion of this Agreement will be excluded from supplying Plasma to Bayer, but Nabi shall still be obligated to provide the annual volumes from one or more other Approved
Bayer Centers operated by Nabi or from other sources that are equivalent to Bayer Approved Centers and that meet the Bayer Specifications and are iQPP Certified. 
 Nabi represents and warrants that all Plasma sold to Bayer under this Agreement will be collected, processed, tested, stored, packaged, labeled and shipped in strict accordance with the Bayer Specifications,
including, but not limited to, testing lab pre-approval and viral marker data, and all applicable law, under the exercise of due care by Nabi, and such Plasma will, when 
  

 2 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 
 delivered to Bayer, be in accordance with the Bayer Specifications and the FDA regulations, and will be fit for the purpose and use
intended by Bayer. Any Plasma which is not produced in accordance with the Bayer Specifications or applicable law or is otherwise not as warranted, can be rejected by Bayer and returned to Nabi, or destroyed if required by the FDA, at Nabi’s
expense. Bayer shall not be obligated to buy or pay for any which does not, in all respects, comply with the Bayer Specifications and applicable law, or is otherwise not as warranted. Nothing contained in this Section, however, shall limit, modify
or waive any other rights or remedies available to Bayer for non-conforming Plasma. If any Center is closed as a result of regulatory sanctions placed on Nabi by the FDA, if Nabi or any Center receives a warning letter or consent decree from the
FDA, or if Nabi or any Center is found by the FDA to have compliance problems that might affect the quality of the Plasma, Nabi must notify Bayer immediately, and in any event not later than five (5) business days after Nabi learns of the
letter, consent decree or problem. If any Center is found by Bayer to be clearly deficient in its compliance with the Bayer Specifications or applicable law, Nabi will have thirty (30) business days to provide, in writing, a corrective action
plan acceptable to Bayer. If the action plan is unacceptable or if the Center cannot provide Plasma within ninety (90) days of any such event, then, at Bayer’s option, this Agreement, including the Plasma volumes, can be modified to
eliminate such Center. 
 5. Price  
 For all Plasma purchased during 2004, the price is to be negotiated (the “Price”). Such Price includes testing for ALT, HIV-1/HIV-2 Antibody, HIV-1 Antigen (p24), Hepatitis B Surface Antigen and Hepatitis C Antibody. As defined in
the Amendment to the Plasma Purchase Agreement dated November 7, 1996, the HIV-1 Antigen (p24) test price is $[*****]/liter. In the event such test is no longer required by the FDA, and Bayer chooses to eliminate this test from its plasma
testing requirements, a mutually negotiated sum, not to exceed $[*****]/liter, will be deducted from the then current Price. 
 Beginning on
January 1, 2005, and on each January 1 thereafter during the term of this Agreement (including any extension and renewal periods), the Price shall be as mutually agreed upon between Nabi and Bayer, no fewer than ninety (90) days prior
to the end of the prior calendar year. 
 If any new government regulations, FDA required tests or changes in the Bayer Specifications
requested by Bayer cause a change in Nabi’s cost of production, Nabi and Bayer agree to re-negotiate the Price then in effect as set forth in this Agreement and the change in Price will be retroactive to the time of the change. 
 In the event the parties are not able to mutually agree on the Price applicable in any given year, the parties shall submit such calculation to an
independent third party, not otherwise employed by either party and reasonably acceptable to both parties, to determine an appropriate price that a similarly situated supplier would charge a similarly situated customer in an “arms length”
transaction having essentially the identical specifications and regulatory requirements as Bayer. In the event the parties cannot agree on an independent third party, then a list of such 
  

 3 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION. 
 available independent third parties shall be submitted to an arbitrator selected from the National Panel of Arbitrators of the American
Arbitration Association (“AAA”) who shall select the independent third party. The Price for all sales pending a final determination of the market price by the independent third party shall be the price previously in effect adjusted in
proportion to the percentage change in the Consumer Price Index, Urban Wage Earners and Clerical Workers, U.S. City Average, All items, Base 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics
(“CPI”) as of the date the matter is submitted to the independent third party. If the change in market price is determined by the independent third party to be more than the Price paid using the CPI as an interim measure, Bayer shall pay
an additional amount reflecting what it would have paid had the newly determined market price been in effect at the start of the year in question; if the newly determined market price is less than the interim CPI based Price, Nabi shall refund to
Bayer the difference between payments received and that which would have been received had the newly determined Price been in effect at the start of the year in question. The parties agree that the Price determined by the independent third party
shall be binding upon the parties and will not be subject to further review. 
 All shipments of Plasma shall be made F.O.B. Center. Bayer will be
responsible for freight charges, insurance, handling and forwarding agent’s fees, taxes, storage and all other charges applicable to the Plasma. All Plasma shall be paid for within thirty (30) business days of receipt by Bayer of an
invoice together with a copy of the Incoming Plasma Control Sheet and the carrier’s Bill of Lading. This documentation must arrive at Bayer no later than four (4) business days after shipment. The Price set forth herein above assumes that
Nabi will provide all softgoods, packaging and testing (such testing includes ALT, HIV1/2 Antibody, HIV 1 Antigen, Hepatitis B Surface Antigen, and Hepatitis C Antibody, but not PCR/NAT tests unless otherwise agreed.). 
 6. Cost Allocation 
 In the event the costs
incurred by Nabi in the collection, packaging, sampling, labeling, testing, processing or storage of Plasma change, the Price per liter shall change accordingly to the extent properly allocable to the Plasma sold to Bayer under this Agreement, using
generally accepted cost accounting principles. The direct costs of any new testing required by the FDA, other governmental agency, or Bayer after the Effective Date shall be borne by Bayer. For purposes of this Agreement, “Direct Costs”
shall mean costs to the extent directly attributable to testing or associated activities, which shall only include the following: (a) personnel wages and salaries and employee benefits allocation; (b) donor fees and donor recruiting fees
paid when applicable; (c) reagents, supplies and materials; (d) laboratory director, physician, physician substitute and consultant services; and (e) contracted and outside services and support costs specifically attributable to the
applicable materials, tests, Plasma or Plasma related activities. In the event a government-mandated program significantly affects Nabi’s costs, then the parties will negotiate how that cost increase or savings will be shared. If the parties
are unable to agree on how that increase or savings will be shared, the matter will be determined by an independent third party according to the process set forth in Section 6. 
  

 4 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
 B. Miscellaneous 
 1.
Inspections 
 Bayer and any authorized representative of Bayer, the Public Health Service, the FDA, and any state, local or
international governmental agency shall have the right to conduct periodic inspections of any Approved Bayer Center and testing facilities. In the case of Bayer, its inspections shall be limited to matters reasonably related to this Agreement and
shall be conducted in conformance with generally accepted industry practices. Bayer will provide Nabi with thirty (30) days’ notice prior to any of its inspections, unless agreed otherwise by the parties. Upon receipt of Bayer’s audit
report, Nabi shall have thirty (30) days to send a response to the appropriate Bayer representative. Nabi agrees to provide Bayer with copies of all written reports (including FDA 483’s) and correspondence between Nabi and any governmental
agency regarding any such inspection or review of records within thirty (30) days of (i) receipt of any such report or correspondence from the governmental agency or (ii) the issuance or delivery of any response or correspondence by
Nabi; provided, however, that in the event the report or correspondence relates to a serious problem that could affect the continuous supply or the quality of the Plasma, then Nabi agrees to use all reasonable efforts to notify Bayer within five
(5) days of receipt of such report or correspondence and to provide Bayer with a copy of such report or correspondence. 
 2. Confidentiality

 The parties agree to maintain the confidentiality of the contents of this Agreement and the dealings between the parties with the
same degree of care as they use to protect their own proprietary, confidential or trade secret information. The parties shall not disclose to any third party any confidential information received from the other hereunder without that other
party’s prior written consent and shall use it only for the purpose of the Agreement. The said obligation of secrecy shall not apply to any information which (a) was in the public domain at the time of its disclosure or thereafter becomes
part of the public domain by publication or otherwise subsequent to the time of disclosure under this Agreement through no fault of the receiving party; or (b) was known to the receiving party or in its possession prior to or at the time of
disclosure as shown by written records; or (c) is independently developed by the receiving party without use of the other party’s confidential information as shown by written documentation; or (d) is disclosed with the written
approval of the disclosing party; or (e) is rightfully furnished to the receiving party by a third party having the authority to disclose such confidential information without restrictions; or (f) is disclosed by law or regulation or in
response to a valid order of a court or other governmental body, or is required for registration of a product by competent authorities, but only to the extent of and for the purpose of such law, regulation, order or registration, and only if the
receiving party first notifies the disclosing party of the required disclosure and permits the disclosing party, at its expense, to seek an appropriate legal remedy to maintain the information in secret. 
  

 5 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
 The above obligations shall survive the termination of this Agreement and shall continue in respect of donor information
without limit of time and in respect of other confidential information for a period of five (5) years. Notwithstanding the foregoing, the parties agree that certain information required in connection with SEC filings concerning the terms of
this Agreement may be disclosed for such SEC filings without the prior approval or consent of either party to this Agreement. 
 3. Relationship of the
Parties 
 The relationship between Bayer and Nabi during the term of this Agreement, including extensions and renewals, is strictly
that of buyer and seller. Neither party is, in any way, the legal representative, agent, joint venture or partner of the other for any purpose whatsoever and neither has any control or authority whatsoever to bind the other party or any other person
with respect to the other party. 
 4. Indemnification 
 Nabi and Bayer hereby indemnify and agree to hold harmless each other and their respective affiliates, agents, employees, officers and directors, from and against any and all claims, losses, liabilities, damages,
attorneys’ fees, costs and expenses (hereinafter “Claims”) which may be sustained by and/or claimed against the other party by virtue of the negligent handling or furnishing of materials or performance of services rendered by the
other party, the willful misconduct by the other party or its officers, employees or agents or any representation or warranty contained in this Agreement being breached, untrue or materially misleading, by omission or otherwise, to the extent of
each party’s insurance coverage. The indemnifying party’s liability shall be reduced to the extent any such claims arise as a result of the indemnified party’s own conduct or negligence. 
 IN NO EVENT WILL EITHER PARTY HAVE ANY LIABILITY FOR ANY LOSS OF INCOME, PROFIT, INTEREST OR SAVINGS BY THE OTHER PARTY OR FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY, ARISING FROM OR RELATED TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, THE SALE OR USE OF ANY PLASMA, REGARDLESS OF THE FORM OF ACTION, AND WHETHER IN CONTRACT, INDEMNITY,
WARRANTY OR TORT INCLUDING WITHOUT LIMITATION STRICT LIABILITY AND NEGLIGENCE OR ANY OTHER LEGAL OR EQUITABLE GROUNDS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS LIMITATION WILL NOT APPLY TO ANY LIABILITY
FOR DAMAGES THAT MAY RESULT FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY. 
 The party from whom indemnity is sought under this
section shall be entitled at its option to defend or control the defense and/or settlement of any such claim. 
  

 6 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
 Each party shall notify the other of any claim or potential claim or liability as soon as it becomes aware that such claim,
potential claim or liability has arisen and shall provide to the other, all-reasonable assistance in respect thereof. 
 5. Insurance

 Each party represents and warrants that it will maintain, at all times during the term of this Agreement, including extensions and
renewals, property damage and general liability and product liability insurance, which shall not contain any contractual exclusion and which shall cover each party’s liability assumed under this Agreement, in an amount not less than $3 million
per occurrence and $5 million in the aggregate. Upon request, each party shall provide the other with a certificate or certificates evidencing such coverage and each party agrees to notify the other party in the event such insurance coverage falls
below the coverage limits set forth above, or is about to be cancelled or terminated for any reason prior to the occurrence of such event. 
 C. Termination 
 1. In addition to any other remedy it may have, either party shall have the right to terminate this Agreement if the other
party fails to remedy and make good any material default in the performance of any material condition or obligation under this Agreement within sixty (60) days of written notice thereof. 
 2. Upon giving the appropriate written notice, either party may terminate this Agreement upon the occurrence of the following event: a proceeding under any bankruptcy,
reorganization, arrangement of debts, insolvency or receivership law is filed by or against the other party, and is not dismissed or stayed within sixty (60) days, or a receiver or trustee is appointed for all or a substantial portion of the
assets of the other party, or the other party makes an assignment for the benefit of its creditors or becomes insolvent. 
 3. Upon termination of this
Agreement, Bayer must pay for any Plasma already delivered and for any Plasma collected under the terms of this Agreement and subsequently delivered to Bayer. 
 4. Notwithstanding anything to the contrary set forth herein, the parties’ obligations under this Agreement in Sections B, E and J shall survive the termination of this Agreement to the extent necessary to give effect to their
reasonable intentions. 
 D. Force Majeure 
 (a) Neither party shall be liable for non-performance caused by strikes, fires, explosions, Acts of God, riots, civil or international war, acts of terrorism, an unexpected downturn in the acceptable donor population
adversely affecting the industry as a whole, inability to obtain Product because of Force Majeure at the producing location, etc. or any other similar or dissimilar cause beyond the reasonable control of either party which renders the 
  

 7 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
 performance of a party’s obligations so difficult or costly as to make such performance commercially unreasonable. The affected party
shall immediately inform the other of such occurrences and the termination thereof. 
 (b) Upon giving notice to the other party, a party
affected by an event of Force Majeure shall be released without any liability on its part from the performance of its obligations under this Agreement, except for the obligation to pay and amounts due and owing hereunder, but only to the extent and
only for the period that its performance of such obligations is prevented by the event of Force Majeure. Such notice shall include a description of the nature of the event of Force Majeure, and its cause and possible consequences. The party claiming
Force Majeure shall promptly notify the other party of the termination of such event. 
 (c) Should the period of Force Majeure continue for
more than six (6) consecutive months, either party may terminate this Agreement upon giving written notice to the other party. 
 E.
Remedies Cumulative; No Waiver 
 The rights and remedies available to Bayer and Nabi under this Agreement or any other agreement among
the parties are cumulative and the exercise of any right or remedy shall not preclude or dismiss Bayer’s or Nabi’s right to pursue any other or additional right or remedy, including, without limitation, any claim for damages. The failure
to exercise any right or remedy in the event of any breach or default shall not constitute a waiver or adversely affect a party’s right to exercise any right or remedy in the future for the same or any other breach or default in the future.

 F. Assignment 
 Neither
party shall assign this Agreement or any of its rights or obligations hereunder without the express written consent of the other party, except as hereinafter provided. Any such consent shall not be unreasonably withheld. With notice to the other
party, either party without the other party’s consent may assign this Agreement to (i) its affiliate, or (ii) a successor to all or substantially all of the assets relating to the business of that party which is involved in the
fulfillment of its obligations under this Agreement, which shall expressly assume in writing the performance of all of the terms and conditions of this Agreement then to be performed by such successor as if it were named herein as a party.

 G. Notice 
 All notices, demands,
requests, consents or approvals required under this Agreement must be in writing and delivered personally to the party or sent by overnight courier service or facsimile, addressed to such party as set forth below: 
  

 8 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
  

			
	To Nabi:	  	Ileana I. Cramer
		
		  	Vice President, Plasma Operations
		
		  	Nabi Biopharmaceuticals
		
		  	5800 Park of Commerce Blvd. NW
		
		  	Boca Raton, FL 33487
		
	With a copy to:	  	General Counsel
		
		  	Nabi Biopharmaceuticals
		
		  	5800 Park of Commerce Blvd. NW
		
		  	Boca Raton, FL 33487
		
	To Bayer:	  	
		
		  	Betty Van Zant
		
		  	Director, Plasma Operations and Testing Services
		
		  	Biological Products
		
		  	Bayer HealthCare LLC
		
		  	79 TW Alexander Drive
		
		  	4101 Research Commons
		
		  	RTP, NC 27709
		
	With copy to	  	Law and Patent Department
		
		  	Bayer HealthCare LLC
		
		  	79 TW Alexander Drive
		
		  	4101 Research Commons
		
		  	RTP, NC 27709

 All such communications will be conclusively deemed to have been received by a party and to be effective when so
delivered personally, or if sent by overnight courier service, on the day after deposit thereof with such service, or if sent by facsimile upon receipt of confirmation of transmission. Nabi and Bayer may change the place to which notices, requests,
and other communications are to be sent to them by giving written notice of such change to the other in the manner set forth above. 
 H.
Number; Gender 
 Unless the context clearly requires otherwise, whenever used in this Agreement, the singular shall include the plural,
the plural shall include the singular and the use of the masculine, feminine or neuter gender shall include all genders. 
  

 9 

 [*****] A CONFIDENTIAL PORTION OF THE MATERIAL HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 
 I. Integration; Effect of Amendment 
 This Agreement, including all attachments, schedules or other agreements specifically incorporated by reference, constitute the entire agreement among the parties with respect to the subject matter of this Agreement
and supersede any and all other prior written or oral agreements, understandings, negotiations or discussions among the parties with respect to the subject matter of this Agreement. This Agreement may not be modified or amended in any respect except
by an instrument in writing signed by both of the parties. 
 J. Choice of Law; Jurisdiction 
 This Agreement has been made by Bayer at its principal place of business in the State of North Carolina. This Agreement shall be governed by, and
construed under, either the internal laws of Florida or the State of North Carolina, without regard to its conflict of laws principles. In the event Bayer chooses to bring an action against Nabi, the jurisdiction shall be in the state or federal
courts of Florida and if Nabi chooses to bring an action against Bayer, the jurisdiction shall be in the state or federal courts of North Carolina.  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized officers as of the day and year first written above. 
  

							
	Bayer HealthCare LLC	 	Nabi Biopharmaceuticals
				
	By:	 	 /s/ Gunnar Riemann
	 	By:	 	 /s/ C. Thomas Johns

	Name:	 	Gunnar Riemann	 	Name:	 	C. Thomas Johns
	Title:	 	President	 	Title:	 	Sr. VP Mfg. Operations

  

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]